Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tempol - Recursion Pharmaceuticals

Next Previous
Drug Profile

Tempol - Recursion Pharmaceuticals

Alternative Names: REC 994; REC-0000994

Latest Information Update: 13 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Utah Research Foundation
  • Developer Recursion Pharmaceuticals
  • Class Analgesics; Anti-inflammatories; Antiglaucomas; Antineoplastics; Antivirals; Cytoprotectives; Eye disorder therapies; Piperidines; Radioprotectives; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cavernous haemangioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cavernous haemangioma

Most Recent Events

  • 05 Feb 2025 Adverse events and efficacy data from a phase II SYCAMORE trial for Cavernous haemangioma released by Recursion Pharmaceuticals
  • 20 Nov 2024 Exscientia has been acquired and merged into Recursion Pharmaceuticals
  • 04 Sep 2024 Recursion Pharmaceuticals announces intention as soon as practical to discuss plans for an additional clinical study

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top